Background {#s0001}
==========

Widespread availability of antiretroviral therapy (ART) has transformed a positive HIV diagnosis from being a death sentence into a chronic manageable disease. To date, no cure exists for HIV, and hence patients must remain on effective ART for the rest of their lives, that makes the development of drug resistance a major public health concern. Sustained viral suppression is of paramount importance if drug resistance is to be prevented. Strategies to ensure optimal adherence to ART are, therefore, an important component of HIV care and treatment. Antiretroviral therapy resistance limits further treatment options, increases treatment programme costs and drug resistance may even be transmitted to others.^[@CIT0001]^ The rising prevalence of HIV drug resistance poses a great threat to the HIV response and has the potential to drive increase in mortality and HIV incidence.^[@CIT0002]^ Several risk factors for the development of HIV drug resistance among patients on ART have been identified.^[@CIT0003]^

HIV treatment in Zimbabwe is based on a public health approach using standard national treatment guidelines.^[@CIT0004]^ Treatment guidelines have periodically changed and are guided by the World Health Organization (WHO). In 2015, Zimbabwe introduced third-line ART in the national programme. Patients failing second-line ART are referred for specialist assessment that includes viral load (VL) and genotype testing prior to recommending third-line medicines. Adherence needs to be reinforced at all times.^[@CIT0004]^

We report the first case of documented four-class HIV drug resistance in Zimbabwe that highlights the possibility of third-line ART failure and transmission of untreatable HIV in resource-limited settings.

Case report {#s0002}
===========

We report the case of an adolescent girl born in July 2000. She tested positive for HIV infection in 2009 and was enrolled into care at Newlands Clinic on 30 July 2009. She is the last born in a family of three children, a paternal orphan and stays with her mother. She was vertically infected, and her mother is accessing ART at the same treatment centre. Both her siblings are HIV negative. She commenced first-line ART on 28 August 2009. [Table 1](#T0001){ref-type="table"} summarises ART regimens received over time and the reasons for regimen changes.

###### 

Antiretroviral therapy history by regimen.

  ART regimen       Start date   End date     Reason for switch
  ----------------- ------------ ------------ -----------------------------
  d4T/3TC/NVP       28/08/2009   30/07/2010   Guideline change
  AZT/3TC/NVP       30/07/2010   10/04/2012   Treatment failure
  LPV/r/AZT/3TC     10/04/2012   20/01/2015   Guideline change
  ATV/r/3TC/ABC     20/01/2015   12/08/2015   Treatment failure
  RAL/DRV/r/3TC     12/08/2015   28/07/2016   Clinic decision
  DTG/DRV/r/3TC     28/07/2016   21/03/2017   Poor adherence
  3TC Monotherapy   21/03/2017   23/01/2018   Change to effective regimen
  DTG/DRV/r/3TC     23/01/2018   12/11/2018   Changed to holding regimen
  ABC/3TC/AZT       12/11/2018   Current      \-

ART, antiretroviral therapy; d4T, stavudine; AZT, zidovudine; 3TC, lamivudine; NVP, nevirapine; ABC, abacavir; r, ritonavir; DRV, darunavir; ATV, atazanavir; LPV, lopinavir; RAL, raltegravir.

Monitoring for ART treatment success was done clinically and immunologically since the initiation of treatment. Routine VL monitoring was added in January 2014. [Figure 1](#F0001){ref-type="fig"} highlights the patient's CD4, VL and ART regimens over time.

![CD4 count, viral load and antiretroviral therapy regimens over time.](HIVMED-20-885-g001){#F0001}

HIV drug resistance testing and third-line response {#s20003}
---------------------------------------------------

A genotypic resistance test was performed on 31 March 2015 after second-line ART failure. Results of the test were interpreted using the Stanford HIV drug resistance guide. We found four major protease inhibitor (PI) resistance-associated mutations (RAMs), that is, M46I, I54V, L76V and V82A. The PI RAMs conferred high-level resistance to atazanavir (ATV), lopinavir, indinavir and saquinavir.

There were three nucleoside reverse transcriptase (NRTI) RAMs, that is, M41L, M184V and T215F, and three non-NRTI RAMs, that is, A98G, K103N and E138A. The RAMs conferred intermediate resistance to abacavir, zidovudine, stavudine, didanosine and rilpivirine. There was high-level resistance to emtricitabine, lamivudine, efavirenz and nevirapine. The virus had low-level resistance to tenofovir and etravirine. [Table 2](#T0002){ref-type="table"} summarises results of the resistance tests conducted during the course of patient management.

###### 

HIV drug resistance test results.

  2015                                          2016                                                             
  --------------------------------------------- ---------------------- -------------- -------------------------- -----------------------
  **NRTI**                                      *M41L, M184V, T215F*                  *M41L, M184V, T215F*       
  Zidovudine                                                           Intermediate                              Intermediate
  Lamivudine                                                           High level                                High level
  Abacavir                                                             Intermediate                              Intermediate
  Emtricitabine                                                        High level                                High level
  Tenofovir                                                            Low level                                 Susceptible
  **NNRTI**                                     *A98G, K103N, E138A*                  *A98G, K103N, E138A*       
  Nevirapine                                                           High level                                High level
  Efavirenz                                                            High level                                High level
  Rilpivirine                                                          Intermediate                              Intermediate
  Etravirine                                                           Low level                                 Low level
  **PI**                                        *M46I, I54V, V82A*                    *M46I, I54V, V82A, L76V*   
  Lopinavir                                                            High level                                High level
  Atazanavir                                                           High level                                High level
  Darunavir                                                            Susceptible                               Intermediate
  **INSTI[†](#TFN0001){ref-type="table-fn"}**                                         *E138K, G140A, Q148R*      
  Elvitegravir                                                                                                   High-level resistance
  Raltegravir                                                                                                    High-level resistance
  Darunavir                                                                                                      High-level resistance

NRTI, nucleoside reverse transcriptase inhibitors; NNRTI, non-nucleoside reverse transcriptase inhibitors; INSTI, integrase strand transfer inhibitor.

, Test done on 14 June 2018.

She was started on third-line ART in August 2015. She has had challenges with treatment adherence because of the high pill burden, and received 3TC monotherapy as a holding therapy from March 2017 (VL was 255 397 copies/mL) to January 2018. She was treated for pulmonary tuberculosis (TB) from 08 August 2017 to 23 January 2018. The TB diagnosis was made based on loss of weight and suggestive chest X-ray findings. She improved clinically on TB treatment, and after completing 6 months of therapy, she recommenced third-line therapy with ritonavir-boosted darunavir, lamivudine and dolutegravir (DTG). She came daily to the clinic for a nurse to observe her and to take third-line medicines for 16 weeks, but her VL remained very high.

An integrase strand transfer inhibitor (INSTI) resistance test was then performed on 14 June 2018. Results showed three integrase inhibitor major RAMs, that is, E138K, G140A and Q148R. The RAMs conferred high-level resistance to DTG, raltegravir (RAL) and elvitegravir (ELV). Trophism assay was performed, and results showed that unfortunately the patient is CXCR4 trophic and hence maraviroc is unlikely to work. The recently approved post-attachment inhibitor, ibalizumab, is not available in the country. She was commenced on a holding regimen of ABC, 3TC and AZT, and her latest VL done on 12 November 2018 was 771 334 copies/mL. Her mother is virologically suppressed on a second-line ART regimen of ATV or ritonavir, AZT and 3TC.

Ethical consideration {#s0004}
=====================

Analysis of routine clinical data is approved by the Medical Research Council of Zimbabwe as part of a larger study, International Epidemiological Databases to Evaluate AIDs (IeDEA Collaboration) (approval no. MRCZ/A/1336). Verbal assent from adolescent and written informed consent from parent were obtained.

Discussion {#s0005}
==========

To our knowledge, this is the first report of a patient with a virus that has developed multi-class drug resistance to all four standard classes of ART, including INSTIs, in Zimbabwe. This patient has HIV with high-level resistance to DTG after previous exposure to RAL. Recently, a case of multi-drug resistant HIV, including resistance to INSTIs, was reported from Botswana^[@CIT0005]^ and a similar case was reported earlier in South Africa.^[@CIT0006]^ Multi-drug resistant HIV could have developed because of a variety of factors, including poor adherence to ART and inadequate psychosocial support -- issues which are frequently encountered among adolescents living with HIV.^[@CIT0007]^ In this case, poor adherence was mainly because of poor family support and lack of motivation for ART when the patient felt clinically well. Poor adherence to previous ART regimens could have led to exposure to DTG monotherapy. Previous studies have shown that monotherapy with DTG has a high rate of resistance selection in the integrase gene through different pathways in case of virologic failure.^[@CIT0008]^

Integrase strand transfer inhibitors are one of the newest class of antiretroviral drugs to be approved for HIV treatment and act by inhibiting the essential HIV protein integrase from inserting the viral DNA genome into the host cell's chromatin. Raltegravir and EVG have been successful in clinical settings, but have low genetic barriers to resistance. Dolutegravir is known to have a very high genetic barrier to resistance and retains activity against RAL- and EVG-resistant viruses.^[@CIT0009],[@CIT0010]^ Zimbabwe has not yet adopted the use of DTG as part of the preferred first-line ART regimens.

Conclusion {#s0006}
==========

This is the first case of recorded four-class HIV drug resistance in Zimbabwe. This adolescent girl cannot be effectively treated with any of the currently available ART regimens in Zimbabwe. Prevention measures such as family planning intervention and safe sex counselling are being taken to minimise the risk of transmission of this multi-class resistant virus.

This case emphasises the need for health workers to continue providing adherence counselling and support for patients who are on ART. Transmission of four-class-resistant HIV is a potential public health disaster.
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